TD Cowen Boosts Bruker (NASDAQ:BRKR) Price Target to $53.00

Bruker (NASDAQ:BRKR) had its price objective hoisted by equities researchers at TD Cowen from $42.00 to $53.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the medical research company’s stock. TD Cowen’s price objective indicates a potential upside of 0.99% from the stock’s previous close.

Several other analysts have also recently commented on BRKR. Wolfe Research raised shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a research note on Wednesday, December 10th. Bank of America boosted their target price on Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Barclays lifted their price objective on Bruker from $45.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Zacks Research upgraded shares of Bruker from a “strong sell” rating to a “hold” rating in a research report on Monday, December 8th. Finally, The Goldman Sachs Group initiated coverage on shares of Bruker in a research note on Tuesday, December 9th. They issued a “sell” rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $52.29.

Bruker Price Performance

NASDAQ:BRKR opened at $52.48 on Wednesday. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81. The firm has a market cap of $7.97 billion, a PE ratio of -328.00, a price-to-earnings-growth ratio of 6.87 and a beta of 1.17. Bruker has a 12 month low of $28.53 and a 12 month high of $64.64. The company’s 50-day moving average price is $45.83 and its two-hundred day moving average price is $39.63.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.12. The company had revenue of $860.50 million during the quarter, compared to analyst estimates of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The company’s revenue was down .5% on a year-over-year basis. During the same quarter last year, the business posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, equities analysts anticipate that Bruker will post 2.69 EPS for the current fiscal year.

Insider Buying and Selling at Bruker

In related news, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total transaction of $243,087.00. Following the transaction, the director owned 35,212 shares of the company’s stock, valued at $1,373,268. This trade represents a 15.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 27.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bruker

Several hedge funds have recently bought and sold shares of the company. Orbis Allan Gray Ltd acquired a new position in shares of Bruker in the 2nd quarter valued at $192,735,000. AQR Capital Management LLC lifted its holdings in Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after acquiring an additional 1,850,215 shares in the last quarter. Sculptor Capital LP grew its stake in Bruker by 18.3% in the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock valued at $126,682,000 after acquiring an additional 476,363 shares during the period. Brown Advisory Inc. raised its position in shares of Bruker by 13.9% during the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock worth $113,142,000 after purchasing an additional 336,026 shares during the period. Finally, Vaughan Nelson Investment Management L.P. lifted its holdings in shares of Bruker by 61.6% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock valued at $67,909,000 after purchasing an additional 796,510 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Key Bruker News

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker acquired the remaining 60% of TOFWERK, taking ownership to 100% — adding ultra-fast TOF mass‑spectrometry for small‑molecule applied markets (air quality, exposomics, foods/flavors). This expands Bruker’s addressable market and product set in applied MS, which could support medium‑term revenue growth if integration and commercialization go smoothly. Bruker Consolidates Ownership of TOFWERK
• Positive Sentiment: TD Cowen raised its price target from $42 to $53 and kept a Hold rating — a modest vote of confidence that helps support the stock’s valuation narrative. TD Cowen price-target update
• Positive Sentiment: Bruker will present at the J.P. Morgan Healthcare Conference — an opportunity for management to provide updates on TOFWERK integration, FY2025 outlook (company guidance: $1.85–$1.90 EPS), and strategic priorities that could influence sentiment. Bruker to Present at J.P. Morgan Healthcare Conference
• Neutral Sentiment: Media/analysis pieces are weighing Bruker’s life‑sciences exposure and mixed valuation signals — useful context but not immediate catalysts. Valuation analysis
• Negative Sentiment: Zacks Research trimmed Q4 2025, FY2025 and FY2027 EPS estimates slightly (Q4 2025: $0.66→$0.65; FY2025: $1.90→$1.89; FY2027: $2.45→$2.44) and retains a Hold — modest downward revisions that can press near‑term sentiment, especially given recent mixed revenue and margin trends.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.